Bone Marrow Transplantation
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
INTERNATIONAL DIFFERENCES IN BASELINE CHARACTERISTICS AND PRACTICE PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION
2023
-
NO EVIDENCE FOR IMPROVED OVERALL SURVIVAL OR PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS AGED 70-75 UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION COMPARED TO A NON-TRANSPLANT STRATEGY
2023
-
WORLDWIDE NETWORK FOR BLOOD AND MARROW TRANSPLANTATION GLOBAL STUDY ON BASELINE CHARACTERISTICS/CLINICAL OUTCOMES IN MULTIPLE MYELOMA PATIENTS UNDERGOING ASCT, A STUDY OFF 61,725 PATIENTS
2023
-
International differences in baseline characteristics and practice patterns in newly diagnosed multiple myeloma (MM) patients undergoing upfront autologous stem cell transplantation
2022
-
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy iN Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial
2020
-
Impact of KIR/HLA Incompatibilities after Posttransplant Cyclophosphamide based T cell-replete Haploidentical Hematopoietic Stem Cell Transplantation
2020
-
Long Term Survival After 2 Years Event Free Survival in Relapsed DLBCL After Autologous Transplantation in the Two Randomized Trials LY.12 and Coral
2020
-
Late hospitalizations among survivors of childhood, adolescence and young adulthood hematopoietic stem-cell transplantation performed for malignant indications
2019
-
Low dose cytarabine may prevent hematologic relapse prior to hsct in patients with AML in first complete remission with minimal residual disease
2019
-
subsequent malignant neoplasms after pediatric, adolescent and young adulthood stem-cell transplantation: a population-based cohort
2019
-
Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD
2018
-
Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: Follow up of a CBMTG randomized trial
2018
-
Intensified conditioning with fludarabine/melphalan plus total body irradiation for acute myeloid leukemia with minimal residual or active disease
2018
-
Ongoing recurrent hospitalization, malignancy, and mortality among survivors of childhood hematopoietic stem cell transplantation performed for non-malignant indications
2018
-
Patient-Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
2018
-
REACH-3 trial design: A Phase 3, Randomized Study to Assess Ruxolitinib over BAT in Patients with Corticosteroid-Refractory Chronic Graft-versus-Host Disease Post Allo-HSCT
2018
-
Inotuzumab ozogamicin and DLI can induce molecular remission in acute lymphoblastic leukemia relapse after allogeneic HSCT
2017
-
Outcome of allogeneic stem cell transplantation for patients with high-risk acute leukemia according to donor type and graft-versus-host disease prophylaxis
2017
-
Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: Updated results of a study by the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL, and the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)
2017
-
Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 trial in patients with AML and ALL
2016
-
Five-Year Outcomes of Halt-MS: High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Severe Relapsing-Remitting Multiple Sclerosis
2016
-
CD34 CELL DOSE IS CORRELATED WITH HEMATOLOGIC RECOVERY BUT NOT CHRONIC GVHD: RESULTS OF THE CBMTG TRIAL COMPARING G-CSF-MOBILIZED PERIPHERAL BLOOD(G-PB) VS G-CSF STIMULATED BONE MARROW(G-BM) IN SIBLING ALLOGRAFTS FOR HEMATOLOGIC MALIGNANCIES
2014
-
DONOR B CELLS POPULATIONS, IFNG-PRODUCING T CELLS, AND CD56BRIGHT NK CELLS CORRELATE WITH DEVELOPMENT OF CHRONIC GVHD IN G-CSF STIMULATED SIBLING DONOR PERIPHERAL BLOOD AND BONE MARROW: RESULTS FROM THE CANADIAN BMT GROUP 0601 RANDOMIZED, PHASE III TRIAL
2014
-
SELECTIVE PHOTODEPLETION OF RECIPIENT-ALLOREACTIVE T-CELLS ENABLES SAFE AND EFFICACIOUS HAPLOIDENTICAL HSCT: INTERIM RESULTS FROM A PHASE II TRIAL IN PATIENTS WITH AML, ALL, AND MDS
2014
-
Costs and cost-effectiveness of allogeneic stem cell transplantation in children are predictable
2013
-
Allogeneic-related stem cell transplantation with reduced-intensity conditioning versus best standard of care in older patients with acute myeloid leukaemia in first complete remission. Interim analysis of a prospective multi center phase III trial
2010
-
Granulocyte-colony stimulating factor - impact on haemostasis in allogeneic stem cell donors. A prospective study
2008
-
Outcomes of reduced-intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma - national review of the Canadian experience by the Canadian Blood and Marrow Transplant Group
2008
-
First 100 donors in the Canadian bone marrow transplant group trial comparing peripheral blood (PB) and bone marrow (BM) in allogeneic transplant.
1998
-
Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis.
58:478-490.
2023
-
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.
57:295-298.
2022
-
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
57:31-37.
2022
-
Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel.
55:1093-1102.
2020
-
Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
54:1077-1081.
2019
-
Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response.
54:442-447.
2019
-
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
54:44-52.
2019
-
Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study.
51:1019-1021.
2016
-
NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD.
49:1513-1520.
2014
-
Malnutrition in patients with chronic GVHD.
49:1300-1306.
2014
-
Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures.
49:116-121.
2014
-
Impact of intensity of conditioning therapy in patients aged 40–60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.
46:516-522.
2011
-
Outcomes of reduced-intensity conditioning allo-SCT for Hodgkin's lymphoma: a national review by the Canadian Blood and Marrow Transplant Group.
45:1253-1255.
2010
-
Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation.
45:521-526.
2010
-
Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation.
44:413-425.
2009
-
A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
44:317-320.
2009
-
Undetectable leukemic blasts and absence of NOD/SCID leukemia-initiating cells in cord blood from a case of maternal AML.
36:269-270.
2005
-
Hematopoietic capacity of adult human skeletal muscle is negligible.
35:663-666.
2005
-
Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation.
35:51-55.
2005
-
Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age.
32:1135-1143.
2003
-
Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34+ absolute counts and subsets.
30:851-860.
2002
-
Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation.
29:967-972.
2002
-
Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation.
29:967-972.
2002
-
Decreased bone mineral density is common after autologous blood or marrow transplantation.
28:387-391.
2001
-
Donor leukocyte infusions for multiple myeloma.
26:1179-1184.
2000
-
Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin’s lymphoma (NHL): results of a provincial strategy.
26:859-864.
2000
-
Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura.
24:641-645.
1999
-
Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial.
24:637-640.
1999
-
Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice.
23:203-209.
1999
-
Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease.
23:397-399.
1999
-
Parentage testing implications of male fertility after allogeneic bone marrow transplantation.
23:187-189.
1999
-
The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.
23:45-51.
1999
-
Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective.
22:1199-1205.
1998
-
CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
22:947-955.
1998
-
Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation.
21:769-773.
1998
-
Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis..
12:405-407.
1993
-
Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group..
8:477-487.
1991
-
Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts..
7:183-191.
1991
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)